Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization

SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.

The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."

At the closing of the sale of CTI's 50% m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... September 16, 2014 Cancer ... and Adoptive T-cell Therapies is a new market ... on the three principal types of therapeutics that ... development in cancer immunotherapy (which is often called ... vaccines and Adoptive cellular immunotherapy. , The ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)... of researchers led by Northeastern University has developed ... junctions and a variety of nanocarbon structures in ... easily scalable, which will allow the researchers to ... use in applications ranging from electronic devices to ... to sports equipment. , Their findings were published ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Cambrex (NYSE:,CBM), a leading life sciences company, announced today ... and Chief Executive Officer,and a member of the Cambrex ... Mack, President and Chief Executive Officer since 1995,and Chairman ... Company will,separate the positions of Board Chairman and CEO ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC Bulletin ... today for the first quarter ended March 31, 2008. ... previous year, including sales,from the newly acquired First Aid ... due primarily to higher than expected,integration costs associated with ...
... supply of top-quality custom cosmesis, hires U.S. ... sales and marketing ... /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s ... the complete operations of LIVINGSKIN, the developer of the unique,and ...
Cached Biology Technology:Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5Touch Bionics acquires LIVINGSKIN 2Touch Bionics acquires LIVINGSKIN 3
(Date:9/15/2014)... naturally across all kingdoms of life and constitute a ... of biological activities. The presence of halogen substituents in ... molecular properties. , One of the Holy ... late-stage, site-specific incorporation of a halogen atom into a ... (one of the most inert chemical bonds known in ...
(Date:9/15/2014)... Australia,s leading coral reef ecologists fears that reef biodiversity ... survival that we once thought. , In an international ... Centre of Excellence for Coral Reef Studies (Coral CoE) ... important species within reef ecosystems. , In coral reefs, ... jobs that keep the ecosystem safe and functioning. ...
(Date:9/15/2014)... of Science and Technology in Society in the College ... has won a 2014 National Science Foundation Faculty Early ... of creating a global nuclear emergency response plan. , ... Plant in March 2011 was a turning point in ... Three of the plant,s six nuclear reactors melted down ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2'Nuclear disasters don't respect national boundaries' 2
... State University have discovered a new method to speed ... advance that could play an important role in making ... an arrayed microchannel reactor and a "laminated architecture" in ... them, are stacked in parallel to provide a high ...
... the first time, completely characterized an important chemical reaction that ... areas. The team,s results indicate that computer models may be ... air quality (smoggy days) by as much as five to ... to people, animals and plants; is the primary ingredient of ...
... made by researchers at the Institut de recherches cliniques ... Noia, Director of the Mechanisms and Genetic Diversity research ... of Experimental Medicine . The team identified a mechanism ... the therapy of some types of lymphoma and leukemia. ...
Cached Biology News:Microreactor speeds nanotech particle production by 500 times 2Study improves accuracy of models for predicting ozone levels in urban areas 2Study improves accuracy of models for predicting ozone levels in urban areas 3Study improves accuracy of models for predicting ozone levels in urban areas 4A discovery could be important for the therapy of lymphoma and leukemia 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
Biology Products: